Roles of Lig3 and XRCC1 Genes in Genome Stability

Lig3 和 XRCC1 基因在基因组稳定性中的作用

基本信息

  • 批准号:
    7843600
  • 负责人:
  • 金额:
    $ 30.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-22 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The human genome is subject to constant attack by endogenous and environmental DNA damaging agents. If unrepaired, DNA lesions will give rise to mutations that in turn may lead to cancer formation. Fortunately, a complex network of DNA repair pathways operates to remove DNA lesions. To assess the biological significance of exposure to environmental DNA damaging agents, it is necessary to understand the details of the complex cellular response to DNA damage. Unlike the conserved LIG1 and LIG4 genes, lower eukaryotes lack a homolog of the mammalian LIG3 gene, which encodes at least three distinct polypeptides. Interestingly, the DNA ligase III?-associated proteins, poly (ADP-ribose) polymerase 1 (PARP-1), XRCC1 and DNA polymerase (Pol) ?, each of which have been implicated in base excision repair and the repair of DNA single strand breaks, are also found only in higher eukaryotes. Using a modified yeast two hybrid assay, we have identified a series of XRCC1 mutants that are defective in specific protein-protein interactions. In Specific Aim 1, we will utilize these mutants to delineate the functional and biological consequences of protein-protein interactions between DNA ligase III?/XRCC1 and other proteins involved in base excision and single strand break repair. Recent studies have increased the repertoire of DNA repair transactions in which DNA ligase III?/XRCC1 participates. In Specific Aim 2, we will determine how DNA ligase III?/XRCC1 is recruited to the DNA nucleotide excision repair machinery and whether this involves an interaction between XRCC1 and PCNA. In preliminary studies, we have identified an interaction between DNA ligase III?/XRCC1 and hRad50/hMre11/Nbs. In Specific Aim 3, we will determine how DNA damage regulates this interaction and whether these proteins act together in an error-prone non-homologous end-joining sub pathway that repairs DNA double strand breaks. Interestingly, this error-prone pathway is up-regulated in cancer cells and may contribute to their characteristic genomic instability. In Specific Aim 4, we will identify and characterize small molecule inhibitors of DNA ligase III. We envision that that these inhibitors will not only be valuable reagents for elucidating the cellular functions of the LIG3 gene products but also may serve as lead compounds for the development of novel anti-cancer agents. PUBLIC HEALTH RELEVANCE: It is well established that genomic instability drives the progression from a normal cell into a cancer cell. Human cells have a complex network of pathways that act together to maintain genome stability. A mechanistic understanding of these pathways will provide fundamental insights into tumor suppression. In addition, genomic instability is a characteristic of tumor cells, indicating that there are differences in the pathways that normally maintain stability. These differences between normal and cancer cells offer an opportunity to develop therapeutic strategies that selectively target cancer cells.
描述(由申请人提供):人类基因组受到内源性和环境DNA损伤剂的不断攻击。如果不进行修复,DNA损伤将引起突变,进而可能导致癌症的形成。幸运的是,一个复杂的DNA修复通路网络可以去除DNA损伤。为了评估暴露于环境DNA损伤剂的生物学意义,有必要了解DNA损伤的复杂细胞反应的细节。与保守的LIG1和LIG4基因不同,低等真核生物缺乏与哺乳动物LIG3基因同源的基因,后者编码至少三种不同的多肽。有趣的是,DNA连接酶III?-相关蛋白、聚(adp -核糖)聚合酶1 (PARP-1)、XRCC1和DNA聚合酶(Pol) ?它们都与碱基切除修复和DNA单链断裂修复有关,也只在高等真核生物中发现。利用改良酵母双杂交实验,我们已经鉴定出一系列XRCC1突变体在特定蛋白质-蛋白质相互作用中存在缺陷。在特异性目标1中,我们将利用这些突变体来描述DNA连接酶III?/XRCC1和其他参与碱基切除和单链断裂修复的蛋白。最近的研究增加了DNA修复交易的曲目,其中DNA连接酶III?/ XRCC1参与。在特异性目标2中,我们将确定DNA连接酶III如何?/XRCC1被招募到DNA核苷酸切除修复机制中,以及这是否涉及XRCC1与PCNA之间的相互作用。在初步研究中,我们已经确定了DNA连接酶III?/XRCC1和hRad50/hMre11/Nbs。在Specific Aim 3中,我们将确定DNA损伤如何调节这种相互作用,以及这些蛋白质是否在一个容易出错的非同源末端连接亚途径中共同作用,修复DNA双链断裂。有趣的是,这种容易出错的途径在癌细胞中被上调,并可能导致其特有的基因组不稳定性。在Specific Aim 4中,我们将鉴定和表征DNA连接酶III的小分子抑制剂。我们设想这些抑制剂不仅将成为阐明LIG3基因产物细胞功能的有价值试剂,而且可能作为开发新型抗癌药物的先导化合物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alan E Tomkinson其他文献

Alan E Tomkinson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alan E Tomkinson', 18)}}的其他基金

Targeting DNA Ligase I in Ovarian Cancer
靶向 DNA 连接酶 I 治疗卵巢癌
  • 批准号:
    10737536
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
The 5th US-EU Conference on Endogenous DNA Damage
第五届美国-欧盟内源性 DNA 损伤会议
  • 批准号:
    8785881
  • 财政年份:
    2014
  • 资助金额:
    $ 30.07万
  • 项目类别:
Cellular Functions of Eukaryotic DNA Ligases
真核 DNA 连接酶的细胞功能
  • 批准号:
    7989620
  • 财政年份:
    2009
  • 资助金额:
    $ 30.07万
  • 项目类别:
Program Leaders of Research Programs
研究项目负责人
  • 批准号:
    7696567
  • 财政年份:
    2008
  • 资助金额:
    $ 30.07万
  • 项目类别:
Strengthen the Research, Training, and Outreach Capacity of the Geographical Management of Cancer Health Disparities Program (GMaP)
加强癌症健康差异地理管理计划 (GMaP) 的研究、培训和推广能力
  • 批准号:
    10372808
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:
Leadership, Planning and Evaluation
领导、规划和评估
  • 批准号:
    10491134
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:
University of New Mexico Cancer Center Support Grant
新墨西哥大学癌症中心支持补助金
  • 批准号:
    9765170
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:
University of New Mexico Cancer Center Support Grant
新墨西哥大学癌症中心支持补助金
  • 批准号:
    10271925
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:
We Ask Because We Care: Enhancing Sexual Orientation and Gender Identity Data Collection in New Mexico Cancer Centers (Ask SOGI)
我们因关心而提问:加强新墨西哥州癌症中心的性取向和性别认同数据收集(询问 SOGI)
  • 批准号:
    10640767
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:
Administrative Supplement to Strengthen NCI-Supported Community Outreach Capacity Through Community Health Educators of the National Outreach Network (NON CHE)
通过国家外展网络 (NON CHE) 的社区健康教育者加强 NCI 支持的社区外展能力的行政补充
  • 批准号:
    10372735
  • 财政年份:
    2005
  • 资助金额:
    $ 30.07万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 30.07万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 30.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 30.07万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 30.07万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了